ArticleSurgery today2026
Upfront surgery for clinical N1 stage II non-small cell lung cancer.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify the high-risk subgroup of outcomes following upfront surgery for clinical (c)-N1 stage II non-small cell lung cancer (NSCLC).
methodsBetween 2009 and 2022, 140 patients underwent upfront lung resection of more than one lobe with mediastinal lymphadenectomy for cN1 stage II NSCLC. The subjects of this retrospective study were 129 of these patients, whose cN1 node was confirmed pathologically as metastasis after surgery. “Continuous cN1” was an N1 node directly involving the primary tumor. Disease-free survival (DFS) and overall survival (OS) were estimated using log-rank tests.
resultsContinuous cN1 was detected in 55 patients (43%). Lobectomy, bilobectomy, and pneumonectomy were performed in 95 (74%), 20 (16%), and 14 (11%) patients, respectively. Bronchoplasty and vascular plasty were performed in 43 patients (33%) and 25 patients (19%), respectively. The pathological nodal status was pN1 only in 92 patients (71%) and pN2 with pN1 in 37 patients (29%). Multivariate analysis identified that a solid component size > 40 mm was an independent predictor of poor DFS (p = 0.020) and OS (p = 0.001).
conclusionsA solid component size of > 40 mm was a poor prognostic factor for the DFS and OS of patients with cN1 stage II NSCLC, suggesting that induction therapy should be considered for this subgroup.
Indexed as
Identifiers
41556996What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.